Literature DB >> 24626788

ADAM17 silencing suppresses the migration and invasion of non-small cell lung cancer.

Xiaohong Lv1, Yang Li1, Ming Qian2, Chengyuan Ma3, Hongyu Jing1, Zhongmei Wen1, Donghua Qian1.   

Abstract

A disintegrin and metalloprotease (ADAM) 17 has been implicated in the tumor progression of various types of solid tumor; however, little is known about its role in non-small cell lung carcinoma (NSCLC). The present study evaluated whether the downregulation of ADAM17 affects cell proliferation, the cell cycle, cell migration and cell invasion in NSCLC. A recombinant lentiviral small hairpin RNA (shRNA) expression vector carrying ADAM17 was constructed and then infected into A549 cells, a human NSCLC cell line. Cell proliferation, cell cycle progression, cell migration and cell invasion were determined following the downregulation of ADAM17 by siRNA. It was revealed that downregulation of ADAM17 expression using an RNA silencing approach in A549 tumor cells significantly suppressed cell proliferation and invasion in vitro, and tumor growth in vivo. These data suggested that ADAM17 is an important regulator of the tumorigenic properties of human NSCLC and may be used as a potential anticancer therapeutic target in NSCLC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24626788     DOI: 10.3892/mmr.2014.2029

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  7 in total

1.  Metallothinein 1E Enhances Glioma Invasion through Modulation Matrix Metalloproteinases-2 and 9 in U87MG Mouse Brain Tumor Model.

Authors:  Hyuk Hur; Hyang-Hwa Ryu; Chun-Hao Li; In Young Kim; Woo-Youl Jang; Shin Jung
Journal:  J Korean Neurosurg Soc       Date:  2016-10-24

2.  ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.

Authors:  Mohamed I Saad; Sultan Alhayyani; Louise McLeod; Liang Yu; Mohammad Alanazi; Virginie Deswaerte; Ke Tang; Thierry Jarde; Julian A Smith; Zdenka Prodanovic; Michelle D Tate; Jesse J Balic; D Neil Watkins; Jason E Cain; Steven Bozinovski; Elizabeth Algar; Tomohiro Kohmoto; Hiromichi Ebi; Walter Ferlin; Christoph Garbers; Saleela Ruwanpura; Irit Sagi; Stefan Rose-John; Brendan J Jenkins
Journal:  EMBO Mol Med       Date:  2019-04       Impact factor: 12.137

Review 3.  ADAM17: An Emerging Therapeutic Target for Lung Cancer.

Authors:  Mohamed I Saad; Stefan Rose-John; Brendan J Jenkins
Journal:  Cancers (Basel)       Date:  2019-08-21       Impact factor: 6.639

4.  Novel Therapeutic Anti-ADAM17 Antibody A9(B8) Enhances EGFR-TKI-Mediated Anticancer Activity in NSCLC.

Authors:  Zheng Yang; Kin Iong Chan; Hang Fai Kwok; Kin Yip Tam
Journal:  Transl Oncol       Date:  2019-08-23       Impact factor: 4.243

5.  ADAM17 promotes lymph node metastasis in gastric cancer via activation of the Notch and Wnt signaling pathways.

Authors:  Wei Li; Daguang Wang; Xuan Sun; Yang Zhang; Lei Wang; Jian Suo
Journal:  Int J Mol Med       Date:  2018-12-17       Impact factor: 4.101

Review 6.  Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?

Authors:  Emile Verhulst; Delphine Garnier; Ingrid De Meester; Brigitte Bauvois
Journal:  Cancers (Basel)       Date:  2022-01-26       Impact factor: 6.639

7.  Semaphorin 5A suppresses the proliferation and migration of lung adenocarcinoma cells.

Authors:  Pin-Hao Ko; Govinda Lenka; Yu-An Chen; Eric Y Chuang; Mong-Hsun Tsai; Yuh-Pyng Sher; Liang-Chuan Lai
Journal:  Int J Oncol       Date:  2019-12-02       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.